Impact of Oral Contraceptives and Metformin on Advanced Lipid Phenotyping in PCOS
Clicks: 5
ID: 324979
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
5 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #43 of 91 articles by views in european journal of endocrinology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Context Combined oral contraceptives (OCPs) and metformin are commonly used in patients with polycystic ovary syndrome (PCOS), who are at elevated risk of dyslipidemia and cardiovascular disease (CVD), but their effects on advanced lipid phenotyping remain unclear. Objective To examine the impact of OCPs and metformin on 1) lipoproteins, 2) apolipoproteins, and 3) cholesterol efflux capacity (CEC, marker of high-density lipoprotein [HDL] function) Design Secondary analysis of the COMET-PCOS randomized clinical trial Setting Two tertiary care reproductive endocrinology clinics Patients or Other Participants Patients with hyperandrogenic PCOS and elevated BMI with paired serum samples for lipoprotein/apolipoprotein analysis (n=180) and cholesterol efflux capacity (n=129) Intervention(s) 24 weeks of metformin, OCP, or OCP + metformin Main Outcome Measure(s) Change in HDL particles (HDL-P), low-density lipoprotein particles (LDL-P), triglyceride-rich lipoprotein particles (TRL-P); apolipoproteins A-I, B, and C-III; and CEC Results . HDL-P concentration increased in the OCP and OCP + metformin arms, while atherogenic small LDL-P increased slightly. Metformin had a largely neutral effect on advanced lipid phenotyping. CEC increased in the OCP arm, though this was attenuated when adjusting for change in ApoA-I (adjusted ratio of geometric means 1.08, 95% CI 0.99-1.17), which increased in all arms. Conclusions In patients with PCOS and high metabolic risk, OCP use resulted in improved HDL-C function and a mixed effect on lipoproteins and apolipoproteins, with no clear benefit from metformin. These findings do not support or refute the cardiovascular risk-benefit of OCP use in PCOS and highlight the need for studies evaluating long-term clinical outcomes.
| Reference Key |
openalex_W7202372187
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Iris Lee, Daniel E Soffer, Alan T. Remaley, Martin P. Playford, Nehal N. Mehta, Christos Coutifaris, Richard S. Legro, Anuja Dokras |
| Journal | european journal of endocrinology |
| Year | 2026 |
| DOI |
10.1093/ejendo/lvag149
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.